AstraZeneca’s Tagrisso Combination Therapy Shows Improved Efficacy in EGFR-mutated NSCLC
UK-headquartered AstraZeneca (AZ; NASDAQ: AZN) has announced interim Phase III data demonstrating that the addition...
Jiangsu Recbio and Yikang Biological Partner to Develop RSV Preventative Vaccine
Jiangsu Recbio Technology Co., Ltd, a China-based biotechnology company, has entered into a product development...
Janssen Reports Positive Results from Phase Ib/II Study of Rybrevant Combo in EGFR-mutated NSCLC
Johnson & Johnson (J&J; NYSE: JNJ) subsidiary Janssen has provided an update on an ongoing...
AstraZeneca’s Enhertu Shows Promising Results in Phase II HER2-mutant NSCLC Trial
AstraZeneca (AZ; NASDAQ: AZN) has released early data from a Phase II trial investigating the...
Innovent Biologics Plans Share Placement to Raise HKD 2.36 Billion for Global Expansion
China-based biotech Innovent Biologics Inc., (HKG: 1801) has issued a notice stating its intention to...
NMPA Pilots Priority Review for Rare Disease Formula Foods, Aims to Reduce Approval Time
The National Medical Products Administration (NMPA) has initiated a pilot program to implement “Priority review...
Huadong Medicine’s Subsidiary Viora Ltd’s V20 Accepted for NMPA Review
China-based Huadong Medicine Co., Ltd (SHE: 000963) has announced that the National Medical Products Administration...
Gan & Lee Pharmaceuticals Initiates Phase II Clinical Study for Weekly Insulin GZR4
Gan & Lee Pharmaceuticals (SHA: 603087), a China-based pharmaceutical company, has announced the dosing of...
Grand Pharmaceutical Receives NMPA Approval for Generic Carbaglu for Hyperammonemia Treatment
China-based Grand Pharmaceutical Group Limited (HKG: 0512) has announced that it has received marketing approval...
JW Therapeutics and 2seventy Bio Expand Partnership for Cell Therapy Development
China-based cell therapy firm JW Therapeutics (HKG: 2126) and US biotech 2seventy Bio Inc., (NASDAQ:...
Wuhan YZY Biopharma Aims to Raise HKD 220 Million in Hong Kong IPO
Wuhan YZY Biopharma Co., Ltd, (HKG: 2496) a biopharmaceutical company specializing in targeted cancer drugs...
Exelixis Secures Global Rights to Develop Insilico Medicine’s USP1 Inhibitor ISM3091
China-based generative artificial intelligence (AI)-driven biotech Insilico Medicine has entered into an exclusive license agreement...
Burning Rock’s CanCatch MRD Product Shows Superiority in Postoperative NSCLC Monitoring
China-based medtech firm Burning Rock Ltd (NASDAQ: BNR) has revealed positive findings from a five-year...
Clover Biopharmaceuticals Launches AdimFlu-S, the Only Imported Quadrivalent Influenza Vaccine in China
China-based Clover Biopharmaceuticals Ltd., (HKG: 2197) has announced the launch of AdimFlu-S (QIS) in mainland...
HutchMed Advances Tazverik Phase II Trial for Follicular Lymphoma in China
China-based HutchMed (HKG: 0013, NASDAQ: HCM) has announced the completion of patient enrollment in a...
Hybio Pharmaceutical’s Semaglutide Clinical Trial Filing Accepted by China’s NMPA
China-based Hybio Pharmaceutical Co., Ltd (SHE: 300199) has announced that the National Medical Products Administration...
Hasten Biopharmaceutical Secures Licensing Deal for LIB’s Lerodalcibep in Greater China
China-based Hasten Biopharmaceutical Co., Ltd has entered into a licensing agreement with US firm LIB...
FDA Extends Pfizer’s Comirnaty Vaccine Indication for Omicron XBB.1.5 Variant
The US Food and Drug Administration (FDA) has granted Pfizer (NYSE: PFE) an indication extension...
Amgen’s Lumakras Combo Shows Promising Results in KRAS-mutated NSCLC Early-Stage Trial
Amgen (NASDAQ: AMGN) has announced positive early-stage data for its KRASG12C inhibitor Lumakras (sotorasib) when...
Gilead’s Trodelvy Combo with MSD’s Keytruda Shows Promise in NSCLC Phase II Trial
Gilead (NASDAQ: GILD) has announced interim data from a Phase II trial assessing the antibody-drug...